89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

Published:2018-07-30 Issue:13 Volume:45 Page:2300-2306
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Bensch Frederike,Brouwers A. H.,Lub-de Hooge M. N.,de Jong J. R.,van der Vegt B.,Sleijfer S.,de Vries E. G. E.,Schröder C. P.

Funder

Dutch A Sister’s Hope foundation

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-018-4099-8/fulltext.html

Reference36 articles.

1. Thomas A, Khan S, Lynch C, et al. Survival by HER2 receptor status in stage IV breast cancer: SEER 2010–2012. J Clin Oncol. 2017;35(suppl; abstr 1032).

2. Lower EE, Glass E, Blau R, et al. HER2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat. 2009;113:301–6.

3. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30:593–9.

4. Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15:7381–8.

5. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601–8.

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer;Journal of Nuclear Medicine;2024-09-05

2. Development of 52Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2;Molecular Imaging and Biology;2024-08-27

3. Radioimmunotheragnosis in Cancer Research;Cancers;2024-08-20

4. In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer;Pharmaceuticals;2024-06-05

5. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3